Lexeo Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets (unaudited)
Condensed Balance Sheets
(Unaudited, in thousands, except share and per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $92,834 | $63,000 |
| Current portion of investments in U.S. Treasury securities, net | 118,869 | 118,767 |
| Prepaid expenses and other current assets | 6,205 | 6,625 |
| Total current assets | 217,908 | 188,392 |
| Non-current portion of investments in U.S. Treasury securities, net | 22,468 | 64,801 |
| Long-term investment | 3,390 | 3,390 |
| Restricted cash | 3,248 | 3,248 |
| Property and equipment, net | 1,121 | 1,139 |
| Lease right-of-use assets - finance | 980 | 1,140 |
| Lease right-of-use assets - operating | 5,783 | 6,578 |
| Total assets | $254,898 | $268,688 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $4,179 | $4,856 |
| Accrued expenses and other current liabilities | 8,847 | 9,277 |
| Current portion of lease liabilities - finance | 489 | 518 |
| Current portion of lease liabilities - operating | 2,177 | 2,157 |
| Total current liabilities | 15,692 | 16,808 |
| Non-current liabilities | ||
| Non-current portion of lease liabilities - finance | 95 | 327 |
| Non-current portion of lease liabilities - operating | 4,050 | 4,884 |
| Total liabilities | 19,837 | 22,019 |
| Commitments and contingencies (Note 11) | ||
| Stockholders' equity: | ||
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of June 30, 2026; 78,622,870 shares issued and 78,622,604 shares outstanding as of June 30, 2026; 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025 | 8 | 7 |
| Treasury stock, at cost, 3,827 common shares as of June 30, 2026 and as of December 31, 2025 | (17) | (17) |
| Additional paid-in capital | 661,565 | 626,625 |
| Accumulated other comprehensive gain (loss) | (298) | 188 |
| Accumulated deficit | (426,197) | (380,134) |
| Total stockholders' equity | 235,061 | 246,669 |
| Total liabilities and stockholders' equity | $254,898 | $268,688 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.